title: Nebivolol in preventing atrial fibrillation following coronary surgery in patients over 60 years of age.
abstract: OBJECTIVE
  Postoperative atrial fibrillation is a common complication after cardiac surgery, with an incidence as high as 20-50%. Increased age is associated with a significant increase in postoperative atrial fibrillation risk. This common complication is associated with higher morbidity and mortality rates. The aim of this study was to assess the efficacy of nebivolol in preventing atrial fibrillation following coronary artery bypass surgery in patients over 60 years of age.
  
  
  METHODS
  In this prospective randomized study, 200 patients who were candidates for elective coronary artery bypass surgery were divided into two groups. The first group was administered with nebivolol and the second group was administered with metoprolol. Treatment was initiated four days prior to surgery, and patients were monitored for atrial fibrillation until discharge. Forty-one patients received 50 mg metoprolol succinate daily, which was initiated minimum 4 days before surgery.
  
  
  RESULTS
  Demographic data were similar in both groups. The incidence of postoperative atrial fibrillation in both groups was similar, with no significant difference being identified [n=20 (20%); n=18 (18%), P=0.718; respectively]. There were not any mortality at both groups during study. Inotropic agent requirement at ICU was similar for both groups [n=12 (12%), n=18 (18%), P=0.32].
  
  
  CONCLUSIONS
  We compared the effectiveness of nebivolol and metoprolol in decreasing the incidence of postoperative atrial fibrillation, and determined that nebivolol was as effective as metoprolol in preventing postoperative atrial fibrillation at patients. Nebivolol may be the drug of choice due to its effects, especially after elective coronary artery bypass surgery.
authors.affiliation: Turgut Ozal Medical Center, Inonu University, Malatya, Turkey.
authors.forename: Nevzat
authors.initials: N
authors.lastname: Erdil
authors.affiliation: Turgut Ozal Medical Center, Inonu University, Malatya, Turkey.
authors.forename: Murat
authors.initials: M
authors.lastname: Kaynak
authors.affiliation: Turgut Ozal Medical Center, Inonu University, Malatya, Turkey.
authors.forename: Köksal
authors.initials: K
authors.lastname: Dönmez
authors.affiliation: Turgut Ozal Medical Center, Inonu University, Malatya, Turkey.
authors.forename: Olcay Murat
authors.initials: OM
authors.lastname: Disli
authors.affiliation: Turgut Ozal Medical Center, Inonu University, Malatya, Turkey.
authors.forename: Bektas
authors.initials: B
authors.lastname: Battaloglu
mesh_terms: D058671:Adrenergic beta-1 Receptor Antagonists / Q000627:therapeutic use*; D000367:Age Factors; D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000188:drug therapy / Q000517:prevention & control*; D001578:Benzopyrans / Q000627:therapeutic use*; D001026:Coronary Artery Bypass / Q000009:adverse effects*; D004983:Ethanolamines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008790:Metoprolol / Q000627:therapeutic use*; D008875:Middle Aged; D000068577:Nebivolol; D011183:Postoperative Complications / Q000188:drug therapy / Q000517:prevention & control*; D011184:Postoperative Period; D011446:Prospective Studies; D015203:Reproducibility of Results; D012307:Risk Factors; D018709:Statistics, Nonparametric; D016896:Treatment Outcome
chemical_list: D058671:Adrenergic beta-1 Receptor Antagonists; D000889:Anti-Arrhythmia Agents; D001578:Benzopyrans; D004983:Ethanolamines; D000068577:Nebivolol; D008790:Metoprolol